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Abstract
Background: Due to its chronic subclinical course and large spectrum of manifestations, leprosy often represents a
diagnostic challenge. Even with proper anti-mycobacteria treatment, leprosy follow up remains challenging: almost
half of leprosy patients may develop reaction episodes. Leprosy is an infrequent complication of solid organ transplant
recipients. This case report illustrates the challenges in diagnosing and managing leprosy and its reactional states in a
transplant recipient.
Case presentation: A 53-year-old man presented 34 months after a successful renal transplantation a
borderline-tuberculoid leprosy with signs of mild type 1 upgrading reaction (T1R). Cutaneous manifestations
were atypical, and diagnosis was only made when granulomatous neuritis was found in a cutaneous biopsy.
He was successfully treated with the WHO recommended multidrug therapy (MDT: rifampicin, dapsone and
clofazimine). However he developed a severe T1R immediately after completion of the MDT but no signs of
allograft rejection. T1R results from flare-ups of the host T-helper-1 cell-mediated immune response against
Mycobacterium leprae antigens in patients with immunologically unstable, borderline forms of leprosy and has
been considered an inflammatory syndrome in many aspects similar to the immune reconstitution inflammatory
syndromes (IRS). The T1R was successfully treated by increasing the prednisone dose without modifying the other
immunosuppressive drugs used for preventing allograft rejection. Immunological study revealed that the patient had a
profound depletion of both in situ and circulating regulatory T-cells and lack of expansion of the Tregs upon M. leprae
stimulation compared to T1R leprosy patients without iatrogenic immunosuppression.
Conclusions: Our case report highlights that leprosy, especially in the transplant setting, requires a high degree
of clinical suspicion and the contribution of histopathology. It also suggests that the development of upgrading
inflammatory syndromes such as T1R can occur despite the sustained immunosuppressors regimen for preventing graft
rejection. Our hypothesis is that the well-known deleterious effects of these immunosuppressors on pathogen-induced
regulatory T-cells contributed to the immunedysregulation and development T1R.
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Background
Due to its chronic and subclinical progression, leprosy
often represents a diagnostic challenge and depends on
a high degree of suspicion by the clinician [1]. Even with
proper anti-mycobacteria treatment, leprosy follow up
remains challenging. Almost half of leprosy patients de-
velop reaction episodes, i.e., worsening of the previous
lesions or appearance of new inflamed lesions and neur-
itis due to exacerbation of the immune response in the
patient. The difficulties in diagnosing and managing lep-
rosy are particularly evident in the transplant setting,
where leprosy is not initially suspected and the diagnosis
is only revealed through histopathology examination of
cutaneous lesions [2].
Post-transplant leprosy is an infrequently reported in-
fectious complication in SOT recipients [2]. However, its
frequency in this population may increase for several
reasons. First, despite WHO initiatives to reduce leprosy
transmission, it remains highly endemic in certain coun-
tries and can even increase due to relaxation of leprosy
surveillance services and other socio-political issues [3].
Second, several highly endemic countries (e.g., Brazil
and India) have been witnessing an increase in their
transplant recipient population [4]. In Brazil, for in-
stance, more than 5000 kidney transplants are per-
formed yearly [5] Third, leprosy in transplant patients
may also become an issue in developed countries due to
increased population movements from underdeveloped to
developed countries (and vice versa). Finally, increased
survival and more aggressive immunosuppressive therapy
may also increase the rate of infectious conditions such as
leprosy that are caused by relatively low virulence patho-
gens with long periods of incubation [6].
This case report illustrates the challenges in diagnosing
and managing leprosy and its reactional states in a trans-
plant recipient. In addition, we were able to follow up
some aspects of regulatory T-cells (Tregs) in peripheral
blood from the patient and in situ, which may give some
insight into the paradox of an individual who develops an
exacerbation of an antigen-specific immune response
while under sustained and potent immunosuppression.
Case presentation
A 53-year-old man with end-stage renal disease due to
hypertensive nephrosclerosis received a kidney from
his sister in 2009. No induction therapy was used, and
immunosuppressive therapy (IT) maintenance con-
sisted of prednisone (5 mg/day), mycophenolate so-
dium (1080 mg/day) and tacrolimus trough levels of
5–7 ng/mL. Thirty-four months post-transplant he
developed erythematous papules on the middle and
proximal phalanges of fingers on both hands. Some of
the papules were ulcerated and with crusts (Fig. 1a). A bi-
opsy of a skin lesion showed chronic epithelioid
granulomas with neuritis on the dermis, a lack of bacilli
by Fite-Faraco staining but a positive immunohistochem-
istry staining (IHC) for BCG on the nerves (Fig. 2). A
diagnosis of BT leprosy was made. The characteristics of
the skin lesions, resembling vasculitis, and the presence of
giant cells and mild edema permeating the granulomas in
the biopsy were suggestive of a mild type 1 upgrading re-
action [7]. A subsequent re-evaluation disclosed left ulnar
and tibial nerve enlargement and loss of sensation in the
affected areas of the hands (Fig. 1b).
He denied contact with individuals with known lep-
rosy, and examination of close relatives was negative for
leprosy, including the sister who donated the kidney
graft; she is doing well and has never developed signs or
symptoms suggestive of leprosy. Two biopsies were
taken from the kidney graft during the patient’s follow
up; histopathology analysis of both did not disclose alter-
ations compatible with leprosy. The patient was born in
the countryside of Bahia State, an area of leprosy high
endemicity, but moved to São Paulo city in 1977. São
Paulo state was classified as a high endemicity area up
to ~1996 but since then there was a marked reduction
in the number of cases and it has been reclassified as a
low endemicity area.
The patient started 12 months of multidrug therapy
(MDT: rifampicin 300 mg/month, dapsone 100 mg/day
and clofazimine 100 mg/day). During all MDT, the im-
munosuppression remained unchanged, except for the
dosage of prednisone, which was kept at 10 mg/day in-
stead of 5 mg/day. The patient completed the MDT
treatment, with full resolution of the skin lesions and
partial improvement of hand anesthesia. One month
after completion of MDT, he presented with painful
erythemato-violaceous papules and edema of both
hands, especially of the fingers of the left hand, with
marked functional impairment (Fig. 1c). A biopsy of a
left hand lesion disclosed a chronic granulomatous
dermatitis characterized by intense lymphomonocytic in-
filtrate, epithelioid granulomas, edema and focal areas of
fibrous exudation, features typical of upgrading T1R lep-
rosy. With this diagnosis, prednisone was increased to
40 mg/day. Mycophenolate sodium and tacrolimus were
maintained, but one month later, mycophenolate was re-
moved due to persistent diarrhea. Four weeks later, as
the manifestations of the upgrading T1R were partially
improved, the prednisone dose was tapered, and everoli-
mus was introduced to replace mycophenolate sodium.
By week 16, the prednisone dose was reduced to 5 mg/
day, and the upgrading T1R achieved complete remission.
The patient remains without relapses at the time of this
publication. However, because of the development of pro-
teinuria, everolimus was subsequently removed, and the
patient remained on prednisone 5 mg/day and tacrolimus,
with trough levels between 5 and 8 ng/mL. Renal function
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was stable throughout follow up (serum creatinine
≤1.5 mg/dL; estimated glomerular filtration rate ≥ 52 mL/
min/1.73 m2).
Tregs evaluation
Circulating Treg numbers were measured by flow cy-
tometry and in situ (biopsies) by IHC (Table 1) (see
Additional file 1 with the strategy and methods for the
Treg measurements). Written informed consent was ob-
tained from the patient before performing the immuno-
assays and the study was approved by the Ethics
Committee of the Clinics Hospital (protocol #107.460).
The patient’s results were compared with those recently
reported in a group of BT leprosy patients with severe
upgrading T1R but not under immunosuppression (T1R
group, n = 14) [8]. The in situ frequency of Tregs in the
first skin lesion biopsy obtained for diagnosis of lep-
rosy while the patient was undergoing a mild reaction
(71 cells/mm2) further decreased when he developed
a severe reaction (55 cells/mm2). Both frequencies
were much lower than the results observed in the bi-
opsies taken during a severe reaction episode in the
T1R group (170 ± 23 cells/mm2).
Peripheral blood Tregs could be assessed only during
severe T1R and in two moments after its remission. The
patient had very low levels of circulating Tregs (CD4
+CD25+CD127low/−Foxp3+ cells) both during the severe
reaction (0.76%) and after its remission (1.2%) 4 months
later, compared with the 3.4 ± 0.4% of circulating Tregs
in the T1R group. Over two years after the reaction epi-
sode, while at a higher tacrolimus trough level (7 ng/mL),
the percentage of Tregs persisted at a subnormal level
(2.35%).
We also examined the capacity of the circulating Tregs
to expand in response to a non-specific stimulus (phyto-
hemagglutinin) and to M. leprae. In agreement with the
ex vivo and in situ low Treg numbers, during the reac-
tion episode, the Tregs of the patient exhibited markedly
reduced expansion with both stimuli (3.0 and 0.93%),
compared to the T1R group (18.9 ± 1.4 and 6.9 ± 0.7%).
Of note, the expansion driven by M. leprae remained
hindered at each of the three times it was tested, while
the expansion driven by phytohemagglutinin increased
to “normal” levels after remission of the severe reaction.
A functional study of the Tregs of the patient was not
possible due to insufficient cell yield. However, we were
able to measure the Tregs expression of CTLA-4, a
molecule tightly related to their suppressive capacity [9].
Both during reaction and after remission, few Tregs
expressed this molecule either ex vivo or in vitro com-
pared to the T1R group.
Discussion
Leprosy can represent a difficult diagnosis because of its
chronic subclinical course and large spectrum of mani-
festations. Since these manifestations are determined at
least partly by the immune response of the patient, one
Fig. 2 Cutaneous biopsy taken for diagnosis of leprosy showing an
inflammatory infiltrate in the dermis with a granuloma within a
nerve (arrow) (400×)
Fig. 1 Cutaneous lesions at the time of diagnosis of leprosy (a and b) and during the severe type 1 reaction (c). a Erythematous papules on the
middle and proximal phalanges of fingers on both hands, some of them ulcerated and with crusts (arrows). b Tibial nerve enlargement
(arrow). c Erythemato-violaceous papules and severe edema of the hand
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would expect atypical leprosy presentations in transplant
recipients; however, most cases reported to date in SOT
recipients presented “regular” manifestations of the in-
fection [2, 10]. Conversely, the patient described here
developed skin lesions resembling vasculitis that did not
raise the suspicion of leprosy. The diagnosis of BT lep-
rosy occurred due to the biopsy of a cutaneous lesion.
This “atypical” presentation was probably related to the
mild upgrading T1R presented by the patient. Signs of
nerve involvement suggestive of leprosy, such as
anesthesia and nerve enlargements, were only detected
in a subsequent dermatologic reevaluation. In fact,
cutaneous biopsy frequently plays a decisive role in the
diagnosis of leprosy. However, in T1R leprosy, the cu-
taneous lesions may harbor no or an insufficient
number of bacilli to be revealed even by appropriate
(e.g., Fite-Faraco) staining. Pathologists should there-
fore rely on the presence of neuritis, which is not al-
ways evident because the inflammatory response can
result in the destruction of nerves. In such instances,
leprosy can be easily misdiagnosed as sarcoidosis or
other granulomatous inflammatory reactions.
Surprisingly, the patient already presented signs of a
mild T1R at diagnosis, which subsided with MDT alone
and became severe just after completion of the MDT.
T1R results from flare-ups of the Th-1 cell-mediated im-
mune response of the host against M. leprae antigens in
patients with immunologically instable, borderline forms
of leprosy [11]. This diagnosis is observed during MDT
but it is also diagnosed either before or after MDT [11].
Paradoxical inflammatory exacerbation in leprosy pa-
tients has been described following BCG vaccination,
probably as a result of increased M. leprae-reactive cell
mediated immunity due to the boosting of the cell-
mediated immunity by homologues M. leprae antigens
present in BCG [12]. Interestingly, in many of these
patients it was associated with T1R. Similarly,
“paradoxical” T1R was also reported in paucibacillary
patients who have been treated with dapsone alone:
the T1R that these patients developed after finishing
the treatment was ascribed to withdrawal of the drug,
since dapsone has been shown to exhibit immunosup-
pressive activity [13]. Hence, these paradoxical reac-
tions can be regarded as inflammatory syndromes in
many aspects similar to the IRS syndromes [14, 15].
The term IRS was originally used to describe the
pathogen-associated inflammatory syndrome presented
by AIDS patients undergoing immune reconstitution
secondary to highly active antiretroviral therapy. How-
ever, IRS-like syndromes have also been described in
non-HIV patients, including patients with chronic granu-
lomatous diseases other than leprosy such as tuberculosis
and paracoccidioidomycosis, who experienced immune-
mediated, paradoxical clinical deterioration during their
follow up [16–18]. In addition, IRS-like syndromes have
been described in post-transplant recipients during anti-
microbial treatment of specific infectious conditions [19].
The few cases of transplant recipients with leprosy reac-
tions reported in the literature represented challenging
diagnosis and management [2, 10, 14, 20]. The develop-
ment of a reaction was in general linked to tapering of im-
munosuppression, although this was not true for every
case [10, 21] and the present case report.
The mechanisms underlying the immune response
flare ups in T1R leprosy patients remain to be investi-
gated. In AIDS patients, the following two mutually
non-exclusive mechanisms can trigger IRIS: exacerbation
of the pathogen-induced T-cell mediated effector re-
sponse and failure of its regulation by antigen-specific
Tregs [22]. In the post-transplant setting, IRS has been
linked to reversal of the anti-inflammatory to the pro-
inflammatory responses as a result of withdrawal or
Table 1 Frequency of Tregs in situ (lesions biopsy), ex vivo (peripheral blood), and in in vitro stimulated PBMC, and CTLA-4 expression
by the Tregs, in the transplant recipient as compared with the T1R group
In situ (biopsy) cells/mm2 Ex vivo (PB) % In vitro (expansion) %
Treg Trega CTLA-4b Trega CTLA-4b
Medium ML PHA Medium ML PHA
At diagnosis 71 - - - - - - - -
Severe reaction 55 0.8 4.1 0.03 0.93 3.0 0.0 0.3 33.6
Remission
(4 months)
- 1.2 6.0 1.0 1.72 15.5 0.2 0.9 44.5
Remission
(2 years)
- 2.35 - 2.0 2.65 22.8 - - -
T1R groupc 170 ± 23 3.4 ± 0.4 24.9 ± 4.8 2.3 ± 0.3 6.9 ± 0.7 18.9 ± 1.4 13.8 ± 3.6 17.8 ± 4.7 72 ± 5.9
PB peripheral blood, PBMC peripheral blood mononuclear cells, Treg regulatory T-cells, ML Mycobacterium leprae antigen, PHA phytohemaglutinnin, T1R type 1
upgrading leprosy reaction
aPercentage of FoxP3+CD127low/− among CD4+CD25+ cells
bPercentage of CTLA-4+ cells among Tregs
cPatients with severe T1R without immunosuppressors (n = 14). Results presented as mean ± SEM
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tapering of the IS regimen [14, 19]. In the present case
report, the severe upgrading T1R was not due to modifi-
cations in the immunosuppressive regimen used for pre-
venting graft rejection, although cessation of the leprosy
MDT with dapsone could have contributed in part to it
[23]. Our hypothesis is that the severe upgrading T1R
was related mainly to the deficient regulation of the M.
leprae antigen-specific effector responses by Tregs.
The different classes of immunosuppressors target dif-
ferent T-cell activation pathways, but share the blockade
of T-cell-mediated effector responses as the main mech-
anism to prevent allograft rejection. However, Tregs have
also been shown to play an important role in graft sur-
vival; deficient recruitment of Tregs to the allograft was
associated with poor graft outcome [24]. The immuno-
suppressors have markedly different effects on Tregs.
Calcineurin inhibitors block the expansion/function of
Tregs, while mTor agents such as everolimus do not, fa-
voring expansion and functional preservation of these
cells [25]. The effect of mycophenolate on Tregs is less
clear, but recent data show that at therapeutic concen-
trations, it potently blocks allospecific Treg function/
expansion [26]. In agreement with this, our patient
showed strikingly reduced in situ and circulating Tregs
during the severe reaction episode compared to a group
of leprosy patients with severe T1R but not under any
immunosuppression. The expansion of Tregs in vitro
was also blocked, particularly when induced with M.
leprae. With T1R resolution, Tregs reacquired a “nor-
mal” rate of expansion upon non-specific stimulation,
but with M. leprae, it remained severely curtailed. The
patient was immunosuppressed with tacrolimus and
mycophenolate throughout leprosy treatment. Unfortu-
nately, Tregs were not assayed in the short period that
everolimus replaced mycophenolate, although it has
been shown that everolimus fails to abrogate the inhibi-
tory effect of tacrolimus on Tregs [27]. Moreover,
although we could not perform functional assays of the
Tregs, we found that the Tregs of the patient had ex-
tremely reduced expression of CTLA-4, a molecule that
has been associated with Treg suppressive function in
transplant recipients [9]. Overall, these data suggest
that immunosuppressors, besides acting on effector
responses, can also block the induction of pathogen-
specific Tregs and result in IRS in transplant recipients
by deregulating the balance between the effector and
regulatory responses. Interestingly, the absence of the
signs of graft rejection in this patient suggests that the
balance between allospecific effectors vs. regulatory re-
sponses and between pathogen-induced effectors vs.
regulatory responses would be differentially regulated.
The rationale for the treatment of IRS or other IRS-
like syndromes is control of the inflammatory process.
Non-steroidal anti-inflammatory drugs can be used, and
in severe cases, corticosteroids are indicated [16–19].
Similarly, severe T1R requires prompt corticosteroid
therapy as it can lead to nerve destruction, being the
leading cause of permanent sequels in leprosy. Our patient
was successfully treated by increasing the prednisone dose
without modifying the other two immunosuppressive
drugs. He resolved the T1R without sequels except for
persistent mild anesthesia in the affected areas of the
hands.
Conclusion
In summary, the present case report highlights the chal-
lenge of diagnosing and managing leprosy in a kidney
transplant recipient. Diagnosis of leprosy, especially in the
transplant setting, requires a high degree of suspicion and
the contribution of histopathology. The patient developed
severe T1R despite the sustained immunosuppressive regi-
men for preventing graft rejection. Our hypothesis is that
the deficiency of pathogen-induced Tregs due to the dele-
terious effects of the immunosuppressors contributed to
this inflammatory syndrome. Further studies are war-
ranted to better understand the role of Tregs in IRS, as
they can potentially help to improve the diagnosis and
management of this still challenging syndrome.
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